Curaleaf Holdings (CURLF) Capital Expenditures (2019 - 2024)
Curaleaf Holdings (CURLF) posted quarterly Capital Expenditures of $80.7 million for Q4 2024, up 56.37% year-over-year from $51.6 million in Q1 2024, and up 390.53% quarter-over-quarter from -$27.8 million in Q3 2024.
Curaleaf Holdings (CURLF) Capital Expenditures (2019 - 2024) Analysis & Trends
Curaleaf Holdings' Capital Expenditures history runs 6 years deep, the most recent figure standing at $80.7 million for Q4 2024.
- In Q4 2024, Capital Expenditures rose 56.37% year-over-year to $80.7 million; the TTM figure through Dec 2024 stood at $89.2 million (down 64.73% YoY), while the FY2025 annual figure was $2.8 million, down 81.78% from the prior year.
- Capital Expenditures for Q4 2024 stood at $80.7 million, up from -$27.8 million in the prior quarter.
- The five-year high for Capital Expenditures was $247.0 million in Q4 2022, with the low at -$54.6 million in Q4 2021.
- The 5-year median for Capital Expenditures is -$27.8 million (2024), against an average of $15.4 million.
- The sharpest annual moves came in 2021 and 2022: Capital Expenditures slumped 135.6% in 2021, then soared 552.45% in 2022.
- Curaleaf Holdings' Capital Expenditures stood at $196.5 million in 2020, then sank by 127.79% to -$54.6 million in 2021, then jumped by 552.45% to $247.0 million in 2022, then slumped by 79.1% to $51.6 million in 2023, then surged by 56.37% to $80.7 million in 2024.
- Business Quant data shows CURLF's Capital Expenditures at $80.7 million in Q4 2024, -$27.8 million in Q3 2024, and $51.6 million in Q4 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.94 Bn | 42.97 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.95 Bn | 39.30 Bn | 2.15 Bn | 104.00 Mn |
| 3 | Zoetis | 31.58 Bn | 29.90 Bn | 1.05 Bn | 117.00 Mn |
| 4 | Takeda Pharmaceutical | 28.63 Bn | 22.83 Bn | 5.10 Bn | -337.60 Mn |
| 5 | United Therapeutics | 22.16 Bn | 19.49 Bn | 683.80 Mn | 108.00 Mn |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn | 52.80 Mn |
| 7 | Neurocrine Biosciences | 15.53 Bn | 15.14 Bn | 935.80 Mn | 7.80 Mn |
| 8 | Elanco Animal Health | 11.76 Bn | 11.23 Bn | 798.00 Mn | 33.00 Mn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.95 Bn | - | - |
| 10 | Curaleaf Holdings | 2.48 Bn | 2.38 Bn | 169.91 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 80.75 Mn |
| Dec 31, 2024 | 80.75 Mn |
| Sep 30, 2024 | -27.79 Mn |
| Sep 30, 2024 | -27.79 Mn |
| Dec 31, 2023 | 51.64 Mn |
| Dec 31, 2023 | 51.64 Mn |
| Sep 30, 2023 | -15.36 Mn |
| Sep 30, 2023 | -15.36 Mn |
| Dec 31, 2022 | 247.01 Mn |
| Dec 31, 2022 | 247.01 Mn |
| Jun 30, 2022 | -30.30 Mn |
| Jun 30, 2022 | -30.30 Mn |
| Mar 31, 2022 | -29.95 Mn |
| Mar 31, 2022 | -29.95 Mn |
| Dec 31, 2021 | -54.59 Mn |
| Dec 31, 2021 | -54.59 Mn |
| Sep 30, 2021 | -44.02 Mn |
| Sep 30, 2021 | -44.02 Mn |
| Jun 30, 2021 | -41.92 Mn |
| Jun 30, 2021 | -41.92 Mn |